{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:26Z","timestamp":1793946506226,"version":"4.8.0"},"reference-count":237,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2026YFHZ0200"],"award-info":[{"award-number":["2026YFHZ0200"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bcp.2026.117949","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:50:33Z","timestamp":1775544633000},"page":"117949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P1","title":["Crosstalk between cytokines and tryptophan metabolism: Therapeutic potential for immune effector cell-associated neurotoxicity syndrome"],"prefix":"10.1016","volume":"250","author":[{"given":"Jianghua","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7096-0102","authenticated-orcid":false,"given":"Dehu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7941-2443","authenticated-orcid":false,"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6230","key":"10.1016\/j.bcp.2026.117949_b0005","first-page":"62","article-title":"Rosenberg","volume":"348","author":"Steven","year":"2015","journal-title":"Restifo NP, Adoptive Cell Transfer as Personalized Immunotherapy for Human Cancer, Science."},{"issue":"7949","key":"10.1016\/j.bcp.2026.117949_b0010","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2026.117949_b0015","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A Paradigm Shift in Cancer Immunotherapy: from Enhancement to Normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"S1","key":"10.1016\/j.bcp.2026.117949_b0025","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/ajh.25445","article-title":"Toxicities of CD19 CAR-T cell immunotherapy","volume":"94","author":"Hirayama","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcp.2026.117949_b0030","doi-asserted-by":"crossref","unstructured":"Wei J, Liu Y, Wang C, Zhang Y, Tong C, Dai G, et al., The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma, Signal Transduct Target Ther. 5(1)(2020):134.","DOI":"10.1038\/s41392-020-00256-x"},{"key":"10.1016\/j.bcp.2026.117949_b0035","series-title":"Huang H","first-page":"e1576","author":"Gu","year":"2022"},{"issue":"4","key":"10.1016\/j.bcp.2026.117949_b0040","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"5","key":"10.1016\/j.bcp.2026.117949_b0045","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"23","key":"10.1016\/j.bcp.2026.117949_b0050","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b0055","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.18596","article-title":"Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells","volume":"201","author":"Galli","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b0060","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2026.117949_b0065","doi-asserted-by":"crossref","unstructured":"Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, et al., Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies, Cell. 183(1)(2020):126-142 e17.","DOI":"10.1016\/j.cell.2020.08.022"},{"issue":"2","key":"10.1016\/j.bcp.2026.117949_b0070","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3324\/haematol.2022.281110","article-title":"Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor-T cell therapy","volume":"108","author":"Berger","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2026.117949_b0075","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-immunol-101220-023458","article-title":"IL-6 Revisited: from Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19","volume":"40","author":"Kishimoto","year":"2022","journal-title":"Annu. Rev. Immunol."},{"issue":"15","key":"10.1016\/j.bcp.2026.117949_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22158334","article-title":"The Role of the IL-6 Cytokine Family in Epithelial-Mesenchymal Plasticity in Cancer Progression","volume":"22","author":"Abaurrea","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2026.117949_b0085","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s12276-021-00649-0","article-title":"Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms","volume":"53","author":"Kang","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bcp.2026.117949_b0090","doi-asserted-by":"crossref","unstructured":"Xiao N, Nie M, Pang H, Wang B, Hu J, Meng X, et al., Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications, Nat Commun. 12(1)(2021):1618.","DOI":"10.1038\/s41467-021-21907-9"},{"issue":"5","key":"10.1016\/j.bcp.2026.117949_b0095","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","article-title":"Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond","volume":"18","author":"Platten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.bcp.2026.117949_b0100","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.immuni.2023.04.011","article-title":"Cytokines as emerging regulators of central nervous system synapses","volume":"56","author":"Zipp","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b0105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nri.2016.123","article-title":"Cytokine networks in neuroinflammation","volume":"17","author":"Becher","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2026.117949_b0110","doi-asserted-by":"crossref","unstructured":"Wu J, Tang L, Du M, Li C, Kou H, Jiang H, et al., Plasma proteomic and metabolomic signatures of B-ALL patients during CAR-T cell therapy, Clin Transl Med. 13(3)(2023):e1225.","DOI":"10.1002\/ctm2.1225"},{"issue":"11","key":"10.1016\/j.bcp.2026.117949_b0115","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/s41590-022-01321-z","article-title":"The neuroimmunology of social-stress-induced sensitization","volume":"23","author":"Biltz","year":"2022","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117949_b0120","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41573-021-00368-1","article-title":"Immune targets for therapeutic development in depression: towards precision medicine","volume":"21","author":"Drevets","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10299","key":"10.1016\/j.bcp.2026.117949_b0125","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117949_b0135","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.bcp.2026.117949_b0140","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.117949_b0145","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.117949_b0150","doi-asserted-by":"crossref","unstructured":"Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, et al., Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events, J Immunother Cancer. 8(2)(2020):e001511.","DOI":"10.1136\/jitc-2020-001511"},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b0155","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2026.117949_b0160","doi-asserted-by":"crossref","unstructured":"Han MW, Jeong SY, Suh CH, Park H, Guenette JP, Huang RY, et al., Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis, Front Neurol. 15(2024):1392831.","DOI":"10.3389\/fneur.2024.1392831"},{"key":"10.1016\/j.bcp.2026.117949_b0165","doi-asserted-by":"crossref","unstructured":"Was H, Borkowska A, Bagues A, Tu L, Liu JYH, Lu Z, et al., Mechanisms of Chemotherapy-Induced Neurotoxicity, Front Pharmacol. 13(2022):750507.","DOI":"10.3389\/fphar.2022.750507"},{"key":"10.1016\/j.bcp.2026.117949_b0170","article-title":"Neurotoxicity of chemotherapeutic agents: mechanisms and mitigation strategies","volume":"1\u201314","author":"Ghosh","year":"2026","journal-title":"Drug Chem. Toxicol."},{"issue":"8","key":"10.1016\/j.bcp.2026.117949_b0175","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2174\/1570159X19666201230151224","article-title":"Immune Checkpoint Inhibitors and Neurotoxicity","volume":"19","author":"Zhao","year":"2021","journal-title":"Curr. Neuropharmacol."},{"issue":"20","key":"10.1016\/j.bcp.2026.117949_b0180","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.117949_b0185","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jad.2021.02.041","article-title":"Prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy: a cross-sectional study","volume":"286","author":"Dai","year":"2021","journal-title":"J. Affect. Disord."},{"issue":"12","key":"10.1016\/j.bcp.2026.117949_b0190","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat. Med."},{"issue":"16","key":"10.1016\/j.bcp.2026.117949_b0195","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.bcp.2026.117949_b0200","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.bcp.2026.117949_b0205","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.bcp.2026.117949_b0210","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in patients with B-cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.bcp.2026.117949_b0215","first-page":"294","article-title":"Clinical Presentation","volume":"28","author":"Grant","year":"2022","journal-title":"Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review, Transplant Cell Ther."},{"issue":"6","key":"10.1016\/j.bcp.2026.117949_b0220","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat. Med."},{"issue":"30","key":"10.1016\/j.bcp.2026.117949_b0225","first-page":"3340","article-title":"Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human","volume":"39","author":"Pan","year":"2021","journal-title":"Phase I Trial, J Clin Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2026.117949_b0230","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.25582","article-title":"Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial","volume":"94","author":"Jiang","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"18","key":"10.1016\/j.bcp.2026.117949_b0235","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bcp.2026.117949_b0240","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bcp.2026.117949_b0245","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","article-title":"Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL","volume":"4","author":"Awasthi","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.bcp.2026.117949_b0250","doi-asserted-by":"crossref","unstructured":"Hong R, Tan Su Yin E, Wang L, Zhao X, Zhou L, Wang G, et al., Tumor Burden Measured by 18F-FDG PET\/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma, Front Oncol. 11(2021):713577.","DOI":"10.3389\/fonc.2021.713577"},{"issue":"21","key":"10.1016\/j.bcp.2026.117949_b0255","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcp.2026.117949_b0260","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","article-title":"Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy","volume":"28","author":"Smith","year":"2022","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.bcp.2026.117949_b0265","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3324\/haematol.2021.280189","article-title":"Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies","volume":"107","author":"Dos Santos","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2026.117949_b0270","doi-asserted-by":"crossref","unstructured":"Li X, Shao M, Zeng X, Qian P, Huang H, Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy, Signal Transduct Target Ther. 6(1)(2021):367.","DOI":"10.1038\/s41392-021-00764-4"},{"issue":"6","key":"10.1016\/j.bcp.2026.117949_b0275","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bcp.2026.117949_b0280","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.bcp.2026.117949_b0285","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.117949_b0290","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ymthe.2020.11.028","article-title":"Single-Cell Transcriptomic Analysis reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia","volume":"29","author":"Li","year":"2021","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.bcp.2026.117949_b0295","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.bcp.2026.117949_b0300","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood-2015-08-664250","article-title":"Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD","volume":"127","author":"Jacoby","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.117949_b0305","doi-asserted-by":"crossref","unstructured":"Chen PH, Lipschitz M, Weirather JL, Jacobson C, Armand P, Wright K, et al., Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy, JCI Insight. 5(12)(2020):e134612.","DOI":"10.1172\/jci.insight.134612"},{"issue":"6","key":"10.1016\/j.bcp.2026.117949_b0310","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s10753-021-01501-3","article-title":"Sepsis-Associated Encephalopathy and Blood-Brain Barrier Dysfunction","volume":"44","author":"Gao","year":"2021","journal-title":"Inflammation"},{"issue":"36","key":"10.1016\/j.bcp.2026.117949_b0315","doi-asserted-by":"crossref","first-page":"22351","DOI":"10.1073\/pnas.2010229117","article-title":"IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome","volume":"117","author":"Kang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.117949_b0320","doi-asserted-by":"crossref","unstructured":"Tsuboi H, Segawa S, Yagishita M, Toko H, Honda F, Kitada A, et al., Activation mechanisms of monocytes\/macrophages in adult-onset Still disease, Front Immunol. 13(2022):953730.","DOI":"10.3389\/fimmu.2022.953730"},{"key":"10.1016\/j.bcp.2026.117949_b0325","doi-asserted-by":"crossref","unstructured":"Deng T, Tang C, Zhang G, Wan X, DAMPs released by pyroptotic cells as major contributors and therapeutic targets for CAR-T-related toxicities, Cell Death Dis. 12(1)(2021):129.","DOI":"10.1038\/s41419-021-03428-x"},{"key":"10.1016\/j.bcp.2026.117949_b0330","doi-asserted-by":"crossref","unstructured":"Liu Y, Fang Y, Chen X, Wang Z, Liang X, Zhang T, et al., Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome, Sci Immunol. 5(43)(2020):eaax7969.","DOI":"10.1126\/sciimmunol.aax7969"},{"issue":"14","key":"10.1016\/j.bcp.2026.117949_b0335","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1074\/jbc.AC119.007558","article-title":"Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators","volume":"294","author":"Sachdeva","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.117949_b0340","doi-asserted-by":"crossref","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, et al., Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies, J Exp Clin Cancer Res. 40(1)(2021):367.","DOI":"10.1186\/s13046-021-02148-6"},{"issue":"7735","key":"10.1016\/j.bcp.2026.117949_b0345","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-018-0774-y","article-title":"Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome","volume":"564","author":"Staedtke","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.117949_b0350","doi-asserted-by":"crossref","unstructured":"Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al., Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome, Transplant Cell Ther. 29(7)(2023):438 e1-438 e16.","DOI":"10.1016\/j.jtct.2023.03.006"},{"key":"10.1016\/j.bcp.2026.117949_b0355","doi-asserted-by":"crossref","unstructured":"Magnusen AF, Hatton SL, Rani R, Pandey MK, Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease, Front Neurol. 12(2021):636139.","DOI":"10.3389\/fneur.2021.636139"},{"issue":"6","key":"10.1016\/j.bcp.2026.117949_b0360","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.it.2015.04.007","article-title":"The choreography of neuroinflammation in Huntington's disease","volume":"36","author":"Crotti","year":"2015","journal-title":"Trends Immunol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117949_b0365","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41582-019-0174-4","article-title":"Immunoneuropsychiatry - novel perspectives on brain disorders","volume":"15","author":"Pape","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bcp.2026.117949_b0370","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","article-title":"Microglia Function in the Central nervous System during Health and Neurodegeneration","volume":"35","author":"Colonna","year":"2017","journal-title":"Annu. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117949_b0375","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1038\/s41380-023-02255-0","article-title":"Brain microvascular endothelial cells and blood-brain barrier dysfunction in psychotic disorders","volume":"28","author":"Lizano","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2026.117949_b0380","doi-asserted-by":"crossref","unstructured":"Gust J, Ponce R, Liles WC, Garden GA, Turtle CJ, Cytokines in CAR T Cell-Associated Neurotoxicity, Front Immunol. 11(2020):577027.","DOI":"10.3389\/fimmu.2020.577027"},{"issue":"8","key":"10.1016\/j.bcp.2026.117949_b0385","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41577-021-00508-z","article-title":"Neuromodulation by the immune system: a focus on cytokines","volume":"21","author":"Salvador","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b0390","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11064-018-2517-8","article-title":"TNF\u03b1 and IL-1\u03b2 but not IL-18 Suppresses Hippocampal Long-Term Potentiation Directly at the Synapse","volume":"44","author":"Prieto","year":"2019","journal-title":"Neurochem. Res."},{"issue":"49","key":"10.1016\/j.bcp.2026.117949_b0395","doi-asserted-by":"crossref","first-page":"17714","DOI":"10.1523\/JNEUROSCI.1253-12.2012","article-title":"Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1\u03b2 via p38 mitogen-activated protein kinase","volume":"32","author":"Tong","year":"2012","journal-title":"J. Neurosci."},{"issue":"18","key":"10.1016\/j.bcp.2026.117949_b0400","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1523\/JNEUROSCI.20-18-06811.2000","article-title":"The inhibitory effect of interleukin-1beta on long-term potentiation is coupled with increased activity of stress-activated protein kinases","volume":"20","author":"Vereker","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2026.117949_b0405","doi-asserted-by":"crossref","unstructured":"Boato F, Hechler D, Rosenberger K, L\u00fcdecke D, Peters EM, Nitsch R, et al., Interleukin-1 beta and neurotrophin-3 synergistically promote neurite growth in vitro, J Neuroinflammation. 8(2011):183.","DOI":"10.1186\/1742-2094-8-183"},{"key":"10.1016\/j.bcp.2026.117949_b0410","doi-asserted-by":"crossref","unstructured":"Park SY, Kang MJ, Han JS, Interleukin-1 beta promotes neuronal differentiation through the Wnt5a\/RhoA\/JNK pathway in cortical neural precursor cells, Mol Brain. 11(1)(2018):39.","DOI":"10.1186\/s13041-018-0383-6"},{"issue":"9","key":"10.1016\/j.bcp.2026.117949_b0415","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/mp.2015.174","article-title":"Brain-borne IL-1 adjusts glucoregulation and provides fuel support to astrocytes and neurons in an autocrine\/paracrine manner","volume":"21","author":"Del Rey","year":"2016","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b0420","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.brainres.2006.04.122","article-title":"Centrally administered interleukin-1 beta sensitizes to the central pressor action of angiotensin II","volume":"1100","author":"Ufnal","year":"2006","journal-title":"Brain Res."},{"issue":"Pt A","key":"10.1016\/j.bcp.2026.117949_b0425","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuropharm.2014.10.027","article-title":"Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability","volume":"96","author":"Vezzani","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2026.117949_b0430","doi-asserted-by":"crossref","unstructured":"Liu X, Chen Y, Wang H, Wei Y, Yuan Y, Zhou Q, et al., Microglia-derived IL-1\u03b2 promoted neuronal apoptosis through ER stress-mediated signaling pathway PERK\/eIF2\u03b1\/ATF4\/CHOP upon arsenic exposure, J Hazard Mater. 417(2021):125997.","DOI":"10.1016\/j.jhazmat.2021.125997"},{"issue":"3","key":"10.1016\/j.bcp.2026.117949_b0435","first-page":"826","article-title":"Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice","volume":"140","author":"Alves","year":"2017","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.bcp.2026.117949_b0440","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.4049\/jimmunol.181.9.6503","article-title":"IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia","volume":"181","author":"Shimizu","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2026.117949_b0445","doi-asserted-by":"crossref","unstructured":"Pan D, Schellhardt L, Acevedo-Cintron JA, Hunter D, Snyder-Warwick AK, Mackinnon SE, et al., IL-4 expressing cells are recruited to nerve after injury and promote regeneration, Exp Neurol. 347(2022):113909.","DOI":"10.1016\/j.expneurol.2021.113909"},{"key":"10.1016\/j.bcp.2026.117949_b0450","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bbi.2014.07.020","article-title":"Vagal nerve stimulation blocks interleukin 6-dependent synaptic hyperexcitability induced by lipopolysaccharide-induced acute stress in the rodent prefrontal cortex","volume":"43","author":"Garcia-Oscos","year":"2015","journal-title":"Brain Behav. Immun."},{"issue":"5","key":"10.1016\/j.bcp.2026.117949_b0455","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cell.2020.02.013","article-title":"Repopulating Microglia Promote Brain Repair in an IL-6-Dependent Manner","volume":"180","author":"Willis","year":"2020","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.bcp.2026.117949_b0460","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s41590-023-01521-1","article-title":"Monocyte-derived IL-6 programs microglia to rebuild damaged brain vasculature","volume":"24","author":"Choi","year":"2023","journal-title":"Nat. Immunol."},{"issue":"11","key":"10.1016\/j.bcp.2026.117949_b0465","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1016\/j.immuni.2021.10.006","article-title":"Prenatal interleukin 6 elevation increases glutamatergic synapse density and disrupts hippocampal connectivity in offspring","volume":"54","author":"Mirabella","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2026.117949_b0470","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.bbi.2019.08.185","article-title":"Increased IL-6 expression in astrocytes is associated with emotionality, alterations in central amygdala GABAergic transmission, and excitability during alcohol withdrawal","volume":"82","author":"Roberts","year":"2019","journal-title":"Brain Behav. Immun."},{"issue":"7","key":"10.1016\/j.bcp.2026.117949_b0475","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.biopsych.2011.11.018","article-title":"The stress-induced cytokine interleukin-6 decreases the inhibition\/excitation ratio in the rat temporal cortex via trans-signaling","volume":"71","author":"Garcia-Oscos","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.bcp.2026.117949_b0480","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1111\/j.1460-9568.2007.05615.x","article-title":"Chronic interleukin-6 alters the level of synaptic proteins in hippocampus in culture and in vivo","volume":"25","author":"Vereyken","year":"2007","journal-title":"Eur. J. Neurosci."},{"issue":"10","key":"10.1016\/j.bcp.2026.117949_b0485","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/1545968319868713","article-title":"Interleukin-6 Disrupts Synaptic Plasticity and Impairs Tissue damage Compensation in Multiple Sclerosis","volume":"33","author":"Stampanoni Bassi","year":"2019","journal-title":"Neurorehabil. Neural Repair"},{"issue":"9","key":"10.1016\/j.bcp.2026.117949_b0490","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/sj.npp.1301612","article-title":"Von Frijtag Drabbe K\u00fcnzel J, et al., Interleukin-6 upregulates neuronal adenosine A1 receptors: implications for neuromodulation and neuroprotection","volume":"33","author":"Biber","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"Pt 11","key":"10.1016\/j.bcp.2026.117949_b0495","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1113\/jphysiol.2009.172312","article-title":"Tumour necrosis factor alpha activates nuclear factor kappaB signalling to reduce N-type voltage-gated Ca2+ current in postganglionic sympathetic neurons","volume":"587","author":"Motagally","year":"2009","journal-title":"J. Physiol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117949_b0500","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.neuron.2014.11.020","article-title":"IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior","volume":"85","author":"Chakrabarty","year":"2015","journal-title":"Neuron"},{"issue":"13","key":"10.1016\/j.bcp.2026.117949_b0505","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1038\/s41386-018-0154-1","article-title":"Resolution of inflammation-induced depression requires T lymphocytes and endogenous brain interleukin-10 signaling","volume":"43","author":"Laumet","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.bcp.2026.117949_b0510","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.immuni.2020.09.018","article-title":"Interleukin-10 Prevents Pathological Microglia Hyperactivation following Peripheral Endotoxin Challenge","volume":"53","author":"Shemer","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2026.117949_b0515","doi-asserted-by":"crossref","unstructured":"Mohamed YT, Salama A, Rabie MA, Abd El Fattah MA, Neuroprotective effect of secukinumab against rotenone induced Parkinson's disease in rat model: Involvement of IL-17, HMGB-1\/TLR4 axis and BDNF\/TrKB cascade, Int Immunopharmacol. 114(2023):109571.","DOI":"10.1016\/j.intimp.2022.109571"},{"key":"10.1016\/j.bcp.2026.117949_b0520","doi-asserted-by":"crossref","unstructured":"Brigas HC, Ribeiro M, Coelho JE, Gomes R, Gomez-Murcia V, Carvalho K, et al., IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer's disease, Cell Rep. 36(9)(2021):109574.","DOI":"10.1016\/j.celrep.2021.109574"},{"issue":"7","key":"10.1016\/j.bcp.2026.117949_b0525","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1021\/acs.molpharmaceut.7b00200","article-title":"Blood-Brain Barrier Penetrating Biologic TNF-\u03b1 Inhibitor for Alzheimer's Disease","volume":"14","author":"Chang","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2026.117949_b0530","doi-asserted-by":"crossref","unstructured":"Ren S, Breuillaud L, Yao W, Yin T, Norris KA, Zehntner SP, et al., TNF-\u03b1-mediated reduction in inhibitory neurotransmission precedes sporadic Alzheimer's disease pathology in young Trem2(R47H) rats, J Biol Chem. 296(2021):100089.","DOI":"10.1074\/jbc.RA120.016395"},{"key":"10.1016\/j.bcp.2026.117949_b0535","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.57513","article-title":"Microglia TREM2(R47H) Alzheimer-linked variant enhances excitatory transmission and reduces LTP via increased TNF-\u03b1 levels","volume":"9","author":"Ren","year":"2020","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.bcp.2026.117949_b0540","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.pain.2010.06.005","article-title":"TNF-\u03b1 contributes to up-regulation of Nav1.3 and Nav1.8 in DRG neurons following motor fiber injury","volume":"151","author":"He","year":"2010","journal-title":"Pain"},{"issue":"28","key":"10.1016\/j.bcp.2026.117949_b0545","doi-asserted-by":"crossref","first-page":"6797","DOI":"10.1523\/JNEUROSCI.3351-16.2017","article-title":"Astrocyte Transforming Growth factor Beta 1 Protects Synapses against A\u03b2 Oligomers in Alzheimer's Disease Model","volume":"37","author":"Diniz","year":"2017","journal-title":"J. Neurosci."},{"issue":"17","key":"10.1016\/j.bcp.2026.117949_b0550","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1523\/JNEUROSCI.2952-16.2017","article-title":"Deficiency in Neuronal TGF-\u03b2 Signaling leads to Nigrostriatal Degeneration and Activation of TGF-\u03b2 Signaling Protects against MPTP Neurotoxicity in mice","volume":"37","author":"Tesseur","year":"2017","journal-title":"J. Neurosci."},{"issue":"7","key":"10.1016\/j.bcp.2026.117949_b0555","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/brain\/awab103","article-title":"CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease","volume":"144","author":"Williams","year":"2021","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.bcp.2026.117949_b0560","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1172\/JCI133737","article-title":"Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease","volume":"130","author":"Roy","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b0565","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbrc.2015.08.104","article-title":"Interferon-gamma inhibits the neuronal differentiation of neural progenitor cells by inhibiting the expression of Neurogenin2 via the JAK\/STAT1 pathway","volume":"466","author":"Ahn","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"27","key":"10.1016\/j.bcp.2026.117949_b0570","doi-asserted-by":"crossref","first-page":"9038","DOI":"10.1523\/JNEUROSCI.5691-09.2010","article-title":"Endogenous interferon gamma directly regulates neural precursors in the non-inflammatory brain","volume":"30","author":"Li","year":"2010","journal-title":"J. Neurosci."},{"issue":"7612","key":"10.1016\/j.bcp.2026.117949_b0575","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nature18626","article-title":"Unexpected role of interferon-\u03b3 in regulating neuronal connectivity and social behaviour","volume":"535","author":"Filiano","year":"2016","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bcp.2026.117949_b0580","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/jnr.23987","article-title":"The antiviral cytokine interferon-gamma restricts neural stem\/progenitor cell proliferation through activation of STAT1 and modulation of retinoblastoma protein phosphorylation","volume":"95","author":"Kulkarni","year":"2017","journal-title":"J. Neurosci. Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.117949_b0585","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1096\/fj.07-099499","article-title":"Interferon-gamma directly induces neurotoxicity through a neuron specific, calcium-permeable complex of IFN-gamma receptor and AMPA GluR1 receptor","volume":"22","author":"Mizuno","year":"2008","journal-title":"FASEB J."},{"issue":"7","key":"10.1016\/j.bcp.2026.117949_b0590","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrd2605","article-title":"Purinergic signalling and disorders of the central nervous system","volume":"7","author":"Burnstock","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.bcp.2026.117949_b0595","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/glia.23519","article-title":"Blocking TNFalpha-driven astrocyte purinergic signaling restores normal synaptic activity during epileptogenesis","volume":"66","author":"Nikolic","year":"2018","journal-title":"Glia"},{"key":"10.1016\/j.bcp.2026.117949_b0600","doi-asserted-by":"crossref","unstructured":"Knight JM, Szabo A, Arapi I, Wu R, Emmrich A, Hackett E, et al., Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy, Commun Med (Lond). 2(1)(2022):49.","DOI":"10.1038\/s43856-022-00116-5"},{"key":"10.1016\/j.bcp.2026.117949_b0605","doi-asserted-by":"crossref","unstructured":"Watne LO, Pollmann CT, Neerland BE, Quist-Paulsen E, Halaas NB, Idland AV, et al., Cerebrospinal fluid quinolinic acid is strongly associated with delirium and mortality in hip-fracture patients, J Clin Invest. 133(2)(2023):e163472.","DOI":"10.1172\/JCI163472"},{"key":"10.1016\/j.bcp.2026.117949_b0610","doi-asserted-by":"crossref","unstructured":"Baumgartner R, Forteza MJ, Ketelhuth DFJ, The interplay between cytokines and the Kynurenine pathway in inflammation and atherosclerosis, Cytokine. 122(2019):154148.","DOI":"10.1016\/j.cyto.2017.09.004"},{"issue":"5","key":"10.1016\/j.bcp.2026.117949_b0615","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/cmi.2017.143","article-title":"IDO1 in cancer: a Gemini of immune checkpoints","volume":"15","author":"Zhai","year":"2018","journal-title":"Cell. Mol. Immunol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117949_b0620","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/npp.2011.277","article-title":"Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis","volume":"37","author":"Zunszain","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.bcp.2026.117949_b0625","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.4049\/jimmunol.1400833","article-title":"Noncanonical NF-kappaB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer","volume":"193","author":"Yu","year":"2014","journal-title":"J. Immunol."},{"issue":"41","key":"10.1016\/j.bcp.2026.117949_b0630","doi-asserted-by":"crossref","first-page":"43267","DOI":"10.18632\/oncotarget.6530","article-title":"IL-27 induces the expression of IDO and PD-L1 in human cancer cells","volume":"6","author":"Carbotti","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bcp.2026.117949_b0635","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/jre.12421","article-title":"Interleukin-12 modulates the immunomodulatory properties of human periodontal ligament cells","volume":"52","author":"Issaranggun Na Ayuthaya","year":"2017","journal-title":"J. Periodontal Res."},{"issue":"2A","key":"10.1016\/j.bcp.2026.117949_b0640","first-page":"931","article-title":"Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma","volume":"22","author":"Liebau","year":"2002","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.bcp.2026.117949_b0645","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.4049\/jimmunol.181.8.5194","article-title":"Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells","volume":"181","author":"Belladonna","year":"2008","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117949_b0650","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4049\/jimmunol.1502615","article-title":"Tolerogenic Phenotype of IFN-gamma-Induced IDO+ Dendritic Cells is Maintained via an Autocrine IDO-Kynurenine\/AhR-IDO Loop","volume":"197","author":"Li","year":"2016","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b0655","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1089\/jir.2005.25.20","article-title":"The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase","volume":"25","author":"Robinson","year":"2005","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.bcp.2026.117949_b0660","doi-asserted-by":"crossref","unstructured":"Mondanelli G, Albini E, Orecchini E, Pallotta MT, Belladonna ML, Ricci G, et al., Pathogenetic Interplay Between IL-6 and Tryptophan Metabolism in an Experimental Model of Obesity, Front Immunol. 12(2021):713989.","DOI":"10.3389\/fimmu.2021.713989"},{"issue":"29","key":"10.1016\/j.bcp.2026.117949_b0665","doi-asserted-by":"crossref","first-page":"E5881","DOI":"10.1073\/pnas.1615280114","article-title":"Inhibition of acute lethal pulmonary inflammation by the IDO-AhR pathway","volume":"114","author":"Lee","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.bcp.2026.117949_b0670","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood.V83.5.1408.1408","article-title":"Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes","volume":"83","author":"Musso","year":"1994","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2026.117949_b0675","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.4049\/jimmunol.0803104","article-title":"Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock","volume":"182","author":"Jung","year":"2009","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117949_b0680","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2567.2008.02986.x","article-title":"Co-operative action of interleukin-10 and interferon-gamma to regulate dendritic cell functions","volume":"127","author":"Yanagawa","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.bcp.2026.117949_b0685","doi-asserted-by":"crossref","unstructured":"Lim JY, Im KI, Lee ES, Kim N, Nam YS, Jeon YW, et al., Enhanced immunoregulation of mesenchymal stem cells by IL-10-producing type 1 regulatory T cells in collagen-induced arthritis, Sci Rep. 6(2016):26851.","DOI":"10.1038\/srep26851"},{"key":"10.1016\/j.bcp.2026.117949_b0690","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/941413","article-title":"IL-4 Inhibits IL-1beta-Induced Depressive-like Behavior and Central Neurotransmitter Alterations","volume":"2015","author":"Park","year":"2015","journal-title":"Mediators Inflamm."},{"issue":"5","key":"10.1016\/j.bcp.2026.117949_b0695","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.bbadis.2015.02.001","article-title":"Expression of the kynurenine pathway enzymes in the pancreatic islet cells","volume":"1852","author":"Liu","year":"2015","journal-title":"Activation by Cytokines and Glucolipotoxicity, Biochim Biophys Acta."},{"key":"10.1016\/j.bcp.2026.117949_b0700","doi-asserted-by":"crossref","unstructured":"Asp L, Johansson AS, Mann A, Owe-Larsson B, Urbanska EM, Kocki T, et al., Effects of pro-inflammatory cytokines on expression of kynurenine pathway enzymes in human dermal fibroblasts, J Inflamm (Lond). 8(2011):25.","DOI":"10.1186\/1476-9255-8-25"},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b0705","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4049\/jimmunol.177.1.130","article-title":"Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO","volume":"177","author":"Belladonna","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2026.117949_b0710","doi-asserted-by":"crossref","unstructured":"Murakami Y, Ishibashi T, Tomita E, Imamura Y, Tashiro T, Watcharanurak K, et al., Depressive symptoms as a side effect of Interferon-alpha therapy induced by induction of indoleamine 2,3-dioxygenase 1, Sci Rep. 6(2016):29920.","DOI":"10.1038\/srep29920"},{"issue":"6","key":"10.1016\/j.bcp.2026.117949_b0715","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jaci.2015.09.055","article-title":"The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases","volume":"137","author":"Harden","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bcp.2026.117949_b0720","doi-asserted-by":"crossref","unstructured":"Huang T, Song J, Gao J, Cheng J, Xie H, Zhang L, et al., Adipocyte-derived kynurenine promotes obesity and insulin resistance by activating the AhR\/STAT3\/IL-6 signaling, Nat Commun. 13(1)(2022):3489.","DOI":"10.1038\/s41467-022-31126-5"},{"key":"10.1016\/j.bcp.2026.117949_b0725","doi-asserted-by":"crossref","unstructured":"Wu Z, Yan L, Lin J, Ke K, Yang W, Constitutive TDO2 expression promotes liver cancer progression by an autocrine IL-6 signaling pathway, Cancer Cell Int. 21(1)(2021):538.","DOI":"10.1186\/s12935-021-02228-9"},{"issue":"3","key":"10.1016\/j.bcp.2026.117949_b0730","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/17435390.2017.1306129","article-title":"Involvement of the cytokine-IDO1-AhR loop in zinc oxide nanoparticle-induced acute pulmonary inflammation","volume":"11","author":"Ho","year":"2017","journal-title":"Nanotoxicology"},{"issue":"3","key":"10.1016\/j.bcp.2026.117949_b0735","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.apsb.2020.07.017","article-title":"Functional metabolomics reveal the role of AHR\/GPR35 mediated kynurenic acid gradient sensing in chemotherapy-induced intestinal damage","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bcp.2026.117949_b0740","doi-asserted-by":"crossref","unstructured":"Zhang S, Fang J, Liu Z, Hou P, Cao L, Zhang Y, et al., Inflammatory cytokines-stimulated human muscle stem cells ameliorate ulcerative colitis via the IDO-TSG6 axis, Stem Cell Res Ther. 12(1)(2021):50.","DOI":"10.1186\/s13287-020-02118-3"},{"issue":"5","key":"10.1016\/j.bcp.2026.117949_b0745","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/aji.12282","article-title":"IL-1beta increases expression of tryptophan 2,3-dioxygenase and stimulates tryptophan catabolism in endometrioma stromal cells","volume":"72","author":"Urata","year":"2014","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.bcp.2026.117949_b0750","doi-asserted-by":"crossref","unstructured":"Liu Y, Liang X, Yin X, Lv J, Tang K, Ma J, et al., Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-gamma-induced immunologic dormancy of tumor-repopulating cells, Nat Commun. 8(2017):15207.","DOI":"10.1038\/ncomms15207"},{"issue":"18","key":"10.1016\/j.bcp.2026.117949_b0755","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1056\/NEJMra1808803","article-title":"Schizophrenia","volume":"381","author":"Marder","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.117949_b0760","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21st century","volume":"29","author":"Howes","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117949_b0765","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/s41380-022-01494-x","article-title":"Schizophrenia: a disorder of broken brain bioenergetics","volume":"27","author":"Henkel","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"Pt B","key":"10.1016\/j.bcp.2026.117949_b0770","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.neuropharm.2016.05.020","article-title":"The kynurenine pathway in schizophrenia and bipolar disorder","volume":"112","author":"Erhardt","year":"2017","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b0775","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41582-023-00904-0","article-title":"Schizophrenia: from neurochemistry to circuits, symptoms and treatments","volume":"20","author":"Howes","year":"2024","journal-title":"Nat. Rev. Neurol."},{"issue":"10","key":"10.1016\/j.bcp.2026.117949_b0780","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/npp.2016.66","article-title":"Tryptophan Metabolism and White Matter Integrity in Schizophrenia","volume":"41","author":"Chiappelli","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.bcp.2026.117949_b0785","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S2215-0366(14)00122-9","article-title":"Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment","volume":"2","author":"Khandaker","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"10.1016\/j.bcp.2026.117949_b0790","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/schbul\/sby024","article-title":"Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations","volume":"44","author":"Muller","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"7","key":"10.1016\/j.bcp.2026.117949_b0795","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1007\/s12035-021-02343-8","article-title":"Inflammatory and Oxidative Pathways are New Drug Targets in Multiple Episode Schizophrenia and Leaky Gut, Klebsiella pneumoniae, and C1q Immune Complexes are additional Drug Targets in first Episode Schizophrenia","volume":"58","author":"Maes","year":"2021","journal-title":"Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117949_b0800","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s12035-019-01737-z","article-title":"The Role of Aberrations in the Immune-Inflammatory Response System (IRS) and the Compensatory Immune-Regulatory Reflex System (CIRS) in Different Phenotypes of Schizophrenia: the IRS-CIRS Theory of Schizophrenia","volume":"57","author":"Roomruangwong","year":"2020","journal-title":"Mol. Neurobiol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117949_b0805","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJMra2033475","article-title":"Depression in Adolescents","volume":"385","author":"Miller","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10161","key":"10.1016\/j.bcp.2026.117949_b0810","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bcp.2026.117949_b0815","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0278-5846(92)90056-K","article-title":"Disturbances in acute phase plasma proteins during melancholia: additional evidence for the presence of an inflammatory process during that illness","volume":"16","author":"Maes","year":"1992","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.bcp.2026.117949_b0820","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0165-0327(95)00028-L","article-title":"Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression","volume":"34","author":"Maes","year":"1995","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bcp.2026.117949_b0825","doi-asserted-by":"crossref","unstructured":"Ga\u0142ecka M, Bli\u017aniewska-Kowalska K, Orzechowska A, Szemraj J, Maes M, Berk M, et al., Inflammatory versus Anti-inflammatory Profiles in Major Depressive Disorders-The Role of IL-17, IL-21, IL-23, IL-35 and Foxp3, J Pers Med. 11(2)(2021).","DOI":"10.3390\/jpm11020066"},{"key":"10.1016\/j.bcp.2026.117949_b0830","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bbi.2015.06.001","article-title":"Cumulative meta-analysis of interleukins 6 and 1\u03b2, tumour necrosis factor \u03b1 and C-reactive protein in patients with major depressive disorder","volume":"49","author":"Haapakoski","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bcp.2026.117949_b0835","doi-asserted-by":"crossref","unstructured":"Sha Q, Madaj Z, Keaton S, Escobar Galvis ML, Smart L, Krzyzanowski S, et al., Cytokines and tryptophan metabolites can predict depressive symptoms in pregnancy, Transl Psychiatry. 12(1)(2022):35.","DOI":"10.1038\/s41398-022-01801-8"},{"key":"10.1016\/j.bcp.2026.117949_b0840","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jad.2023.07.078","article-title":"The kynurenine pathway in major depressive disorder under different disease states: a systematic review and meta-analysis","volume":"339","author":"Ou","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bcp.2026.117949_b0845","doi-asserted-by":"crossref","unstructured":"Lin Y, Wang L, Meng S, Liu J, Li X, Wang W, et al., 3-hydroxykynurenine increase in kynurenine pathway driven bisphenol F induced anxiety- and depression-like behaviors, Sci Total Environ. 995(2025):180073.","DOI":"10.1016\/j.scitotenv.2025.180073"},{"issue":"3","key":"10.1016\/j.bcp.2026.117949_b0850","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1515\/revneuro-2022-0047","article-title":"The role and mechanism of tryptophan - kynurenine metabolic pathway in depression","volume":"34","author":"Gong","year":"2023","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.bcp.2026.117949_b0855","doi-asserted-by":"crossref","unstructured":"Bansal Y, Singh R, Sodhi RK, Khare P, Dhingra R, Dhingra N, et al., Kynurenine monooxygenase inhibition and associated reduced quinolinic acid reverses depression-like behaviour by upregulating Nrf2\/ARE pathway in mouse model of depression: In-vivo and In-silico studies, Neuropharmacology. 215(2022):109169.","DOI":"10.1016\/j.neuropharm.2022.109169"},{"key":"10.1016\/j.bcp.2026.117949_b0860","doi-asserted-by":"crossref","unstructured":"Fukuda K, Etiological classification of depression based on the enzymes of tryptophan metabolism, BMC Psychiatry. 14(2014):372.","DOI":"10.1186\/s12888-014-0372-y"},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b0865","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1056\/NEJMra1906193","article-title":"Bipolar Disorder","volume":"383","author":"Carvalho","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10265","key":"10.1016\/j.bcp.2026.117949_b0870","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(20)31544-0","article-title":"Bipolar disorders","volume":"396","author":"McIntyre","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.117949_b0875","doi-asserted-by":"crossref","unstructured":"Anderson G, Maes M, Bipolar disorder: role of immune-inflammatory cytokines, oxidative and nitrosative stress and tryptophan catabolites, Curr Psychiatry Rep. 17(2)(2015):8.","DOI":"10.1007\/s11920-014-0541-1"},{"key":"10.1016\/j.bcp.2026.117949_b0880","doi-asserted-by":"crossref","unstructured":"Zhang P, Huang H, Gao X, Jiang J, Xi C, Wu L, et al., Involvement of Kynurenine Metabolism in Bipolar Disorder: An Updated Review, Front Psychiatry. 12(2021):677039.","DOI":"10.3389\/fpsyt.2021.677039"},{"issue":"7","key":"10.1016\/j.bcp.2026.117949_b0885","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1038\/s41380-020-00913-1","article-title":"The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites","volume":"26","author":"Bartoli","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.bcp.2026.117949_b0890","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000520152","article-title":"The Role of Kynurenines in Cognitive Dysfunction in Bipolar Disorder","volume":"81","author":"Hebbrecht","year":"2022","journal-title":"Neuropsychobiology"},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b0895","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bdi.12529","article-title":"Total sleep time and kynurenine metabolism associated with mood symptom severity in bipolar disorder","volume":"20","author":"Mukherjee","year":"2018","journal-title":"Bipolar Disord."},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b0900","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/bdi.12814","article-title":"A mood state-specific interaction between kynurenine metabolism and inflammation is present in bipolar disorder","volume":"22","author":"van den Ameele","year":"2020","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.bcp.2026.117949_b0905","doi-asserted-by":"crossref","unstructured":"Perez-De La Cruz V, Carrillo-Mora P, Santamaria A, Quinolinic Acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms, Int J Tryptophan Res. 5(2012):1-8.","DOI":"10.4137\/IJTR.S8158"},{"issue":"10284","key":"10.1016\/j.bcp.2026.117949_b0910","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b0915","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/glia.1072","article-title":"Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro","volume":"35","author":"Lue","year":"2001","journal-title":"Glia"},{"key":"10.1016\/j.bcp.2026.117949_b0920","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.bbi.2016.03.002","article-title":"Indoleamine-2,3-dioxygenase mediates neurobehavioral alterations induced by an intracerebroventricular injection of amyloid-beta1-42 peptide in mice","volume":"56","author":"Souza","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bcp.2026.117949_b0925","doi-asserted-by":"crossref","unstructured":"Chatterjee P, Zetterberg H, Goozee K, Lim CK, Jacobs KR, Ashton NJ, et al., Plasma neurofilament light chain and amyloid-\u03b2 are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease, J Neuroinflammation. 16(1)(2019):186.","DOI":"10.1186\/s12974-019-1567-4"},{"issue":"12","key":"10.1016\/j.bcp.2026.117949_b0930","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1002\/alz.13162","article-title":"Higher concentrations of kynurenic acid in CSF are associated with the slower clinical progression of Alzheimer's disease","volume":"19","author":"Knapskog","year":"2023","journal-title":"Alzheimers Dement."},{"issue":"26","key":"10.1016\/j.bcp.2026.117949_b0935","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1523\/JNEUROSCI.1381-04.2004","article-title":"Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain","volume":"24","author":"Caricasole","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2026.117949_b0940","doi-asserted-by":"crossref","unstructured":"Duan Z, Zhang S, Liang H, Xing Z, Guo L, Shi L, et al., Amyloid beta neurotoxicity is IDO1-Kyn-AhR dependent and blocked by IDO1 inhibitor, Signal Transduct Target Ther. 5(1)(2020):96.","DOI":"10.1038\/s41392-020-0188-9"},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b0945","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12035-020-02046-6","article-title":"Potential Mechanism of Cellular Uptake of the Excitotoxin Quinolinic Acid in Primary Human Neurons","volume":"58","author":"Braidy","year":"2021","journal-title":"Mol. Neurobiol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117949_b0950","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson's disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117949_b0955","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and Treatment of Parkinson Disease: a Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2026.117949_b0960","doi-asserted-by":"crossref","unstructured":"Fan X, Xiao Z, Chen Y, Yang H, Diao M, Hu W, et al., Interactions between gut microbiota and parkinson's disease: the role of tryptophan metabolism, Cell Commun Signal. 23(1)(2025):424.","DOI":"10.1186\/s12964-025-02393-8"},{"issue":"11","key":"10.1016\/j.bcp.2026.117949_b0965","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/mds.28202","article-title":"Tryptophan Metabolites are Associated with Symptoms and Nigral Pathology in Parkinson's Disease","volume":"35","author":"Heilman","year":"2020","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.bcp.2026.117949_b0970","article-title":"Peripheral Tryptophan - Kynurenine Metabolism Associated with Metabolic Syndrome is different in Parkinson's and Alzheimer's Diseases","volume":"1","author":"Oxenkrug","year":"2017","journal-title":"Endocrinol Diabetes Metab J."},{"issue":"8","key":"10.1016\/j.bcp.2026.117949_b0975","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1007\/s12035-017-0845-3","article-title":"Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson's Disease","volume":"55","author":"Chang","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bcp.2026.117949_b0980","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pneurobio.2015.12.009","article-title":"Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease","volume":"155","author":"Lim","year":"2017","journal-title":"Prog. Neurobiol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117949_b0985","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jnc.14104","article-title":"Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia","volume":"142","author":"Havelund","year":"2017","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.bcp.2026.117949_b0990","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0306-4522(96)00655-0","article-title":"Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid","volume":"78","author":"Miranda","year":"1997","journal-title":"Neuroscience"},{"issue":"18","key":"10.1016\/j.bcp.2026.117949_b0995","doi-asserted-by":"crossref","DOI":"10.1016\/0024-3205(90)90376-3","article-title":"Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism","volume":"47","author":"Graham","year":"1990","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2026.117949_b1000","doi-asserted-by":"crossref","unstructured":"Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, et al., Huntington disease, Nat Rev Dis Primers. 1(2015):15005.","DOI":"10.1038\/nrdp.2015.5"},{"issue":"15","key":"10.1016\/j.bcp.2026.117949_b1005","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","article-title":"Differential loss of striatal projection neurons in Huntington disease","volume":"85","author":"Reiner","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.117949_b1010","doi-asserted-by":"crossref","unstructured":"Stoberl N, Donaldson J, Binda CS, McAllister B, Hall-Roberts H, Jones L, et al., Mutant huntingtin confers cell-autonomous phenotypes on Huntington's disease iPSC-derived microglia, Sci Rep. 13(1)(2023):20477.","DOI":"10.1038\/s41598-023-46852-z"},{"issue":"8","key":"10.1016\/j.bcp.2026.117949_b1015","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease","volume":"205","author":"Bjorkqvist","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2026.117949_b1020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbi.2014.09.011","article-title":"Plasma inflammatory biomarkers for Huntington's disease patients and mouse model","volume":"44","author":"Chang","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bcp.2026.117949_b1025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.pbb.2015.03.002","article-title":"Central nervous system-specific alterations in the tryptophan metabolism in the 3-nitropropionic acid model of Huntington's disease","volume":"132","author":"Veres","year":"2015","journal-title":"Pharmacol. Biochem. Behav"},{"issue":"3","key":"10.1016\/j.bcp.2026.117949_b1030","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.nbd.2004.07.006","article-title":"Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease","volume":"17","author":"Guidetti","year":"2004","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b1035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-510X(94)00280-2","article-title":"Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases","volume":"130","author":"Jauch","year":"1995","journal-title":"J. Neurol. Sci."},{"issue":"Pt 5","key":"10.1016\/j.bcp.2026.117949_b1040","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/brain\/115.5.1249","article-title":"Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease","volume":"115","author":"Heyes","year":"1992","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b1045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/14728222.2019.1549231","article-title":"Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington's disease","volume":"23","author":"Boros","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bcp.2026.117949_b1050","doi-asserted-by":"crossref","unstructured":"Bains M, Kaur J, Akhtar A, Kuhad A, Sah SP, Anti-inflammatory effects of ellagic acid and vanillic acid against quinolinic acid-induced rat model of Huntington's disease by targeting IKK-NF-kappaB pathway, Eur J Pharmacol. 934(2022):175316.","DOI":"10.1016\/j.ejphar.2022.175316"},{"issue":"3","key":"10.1016\/j.bcp.2026.117949_b1055","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1471-4159.2005.03070.x","article-title":"Tryptophan metabolism and oxidative stress in patients with Huntington's disease","volume":"93","author":"Stoy","year":"2005","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b1060","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/cns.13569","article-title":"Peripheral inflammation and blood-brain barrier disruption: effects and mechanisms","volume":"27","author":"Huang","year":"2021","journal-title":"CNS Neurosci. Ther."},{"issue":"18","key":"10.1016\/j.bcp.2026.117949_b1065","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00018-014-1625-0","article-title":"Developmental and pathological angiogenesis in the central nervous system","volume":"71","author":"Vallon","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"issue":"12","key":"10.1016\/j.bcp.2026.117949_b1070","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.it.2006.10.004","article-title":"Angiopoietins: a link between angiogenesis and inflammation","volume":"27","author":"Fiedler","year":"2006","journal-title":"Trends Immunol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117949_b1075","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrd.2016.278","article-title":"Therapeutic targeting of the angiopoietin-TIE pathway","volume":"16","author":"Saharinen","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.bcp.2026.117949_b1080","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood-2003-10-3685","article-title":"The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies","volume":"103","author":"Fiedler","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bcp.2026.117949_b1085","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/jnen\/nly064","article-title":"Neuropathology of a Case with Fatal CAR T-Cell-Associated Cerebral Edema","volume":"77","author":"Torre","year":"2018","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117949_b1090","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/bloodadvances.2022008119","article-title":"GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients","volume":"7","author":"Gust","year":"2023","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.bcp.2026.117949_b1095","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0887-8994(01)00345-9","article-title":"Cytotoxic edema and interleukin-6 in hypertensive encephalopathy","volume":"26","author":"Takano","year":"2002","journal-title":"Pediatr. Neurol."},{"issue":"7323","key":"10.1016\/j.bcp.2026.117949_b1100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature09522","article-title":"Pericytes regulate the blood-brain barrier","volume":"468","author":"Armulik","year":"2010","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.bcp.2026.117949_b1105","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1182\/bloodadvances.2022007456","article-title":"Host metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy","volume":"7","author":"Jalota","year":"2022","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/j.bcp.2026.117949_b1110","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1158\/2326-6066.CIR-22-0418","article-title":"Hypophosphatemia due to increased Effector Cell Metabolic activity is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy","volume":"10","author":"Tang","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"10.1016\/j.bcp.2026.117949_b1115","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/bloodadvances.2021006144","article-title":"Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment","volume":"6","author":"Schoeberl","year":"2022","journal-title":"Blood Adv."},{"issue":"25","key":"10.1016\/j.bcp.2026.117949_b1120","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bcp.2026.117949_b1125","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jir.1997.17.589","article-title":"Quinolinic acid production by macrophages stimulated with IFN-gamma","volume":"17","author":"Pemberton","year":"1997","journal-title":"TNF-Alpha, and IFN-Alpha, J Interferon Cytokine Res."},{"key":"10.1016\/j.bcp.2026.117949_b1130","doi-asserted-by":"crossref","unstructured":"Heyes MP, Saito K, Major EO, Milstien S, Markey SP, Vickers JH, A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate, Brain. 116 (Pt 6)(1993):1425-50.","DOI":"10.1093\/brain\/116.6.1425"},{"issue":"3","key":"10.1016\/j.bcp.2026.117949_b1135","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1042\/BST20230742","article-title":"The high-affinity tryptophan uptake transport system in human cells","volume":"52","author":"Wakasugi","year":"2024","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bcp.2026.117949_b1140","doi-asserted-by":"crossref","unstructured":"Albrecht J, Zielinska M, Exchange-mode glutamine transport across CNS cell membranes, Neuropharmacology. 161(2019):107560.","DOI":"10.1016\/j.neuropharm.2019.03.003"},{"issue":"3","key":"10.1016\/j.bcp.2026.117949_b1145","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00109-023-02289-5","article-title":"Activation of aryl hydrocarbon receptor (AhR) in Alzheimer's disease: role of tryptophan metabolites generated by gut host-microbiota","volume":"101","author":"Salminen","year":"2023","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.bcp.2026.117949_b1150","doi-asserted-by":"crossref","unstructured":"Barbosa-Silva MC, Lima MN, Battaglini D, Robba C, Pelosi P, Rocco PRM, et al., Infectious disease-associated encephalopathies, Crit Care. 25(1)(2021):236.","DOI":"10.1186\/s13054-021-03659-6"},{"key":"10.1016\/j.bcp.2026.117949_b1155","doi-asserted-by":"crossref","unstructured":"Baur K, Heim D, Beerlage A, Poerings AS, Kopp B, Medinger M, et al., Dasatinib for treatment of CAR T-cell therapy-related complications, J Immunother Cancer. 10(12)(2022):e005956.","DOI":"10.1136\/jitc-2022-005956"},{"key":"10.1016\/j.bcp.2026.117949_b1160","doi-asserted-by":"crossref","unstructured":"Wehrli M, Gallagher K, Chen YB, Leick MB, McAfee SL, El-Jawahri AR, et al., Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS), J Immunother Cancer. 10(1)(2022):e003847.","DOI":"10.1136\/jitc-2021-003847"},{"issue":"7","key":"10.1016\/j.bcp.2026.117949_b1165","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther."},{"issue":"8","key":"10.1016\/j.bcp.2026.117949_b1170","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117949_b1175","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1177\/10781552221140320","article-title":"Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting","volume":"29","author":"Lipe","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"21","key":"10.1016\/j.bcp.2026.117949_b1180","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1182\/bloodadvances.2023009961","article-title":"A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome","volume":"7","author":"Jacobson","year":"2023","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.bcp.2026.117949_b1185","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:38:13Z","timestamp":1793943493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226002820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":237,"alternative-id":["S0006295226002820"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117949","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crosstalk between cytokines and tryptophan metabolism: Therapeutic potential for immune effector cell-associated neurotoxicity syndrome","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117949"}}